Product Name
CLRN1, siRNA
Full Product Name
CLRN1 siRNA (Mouse)
Product Synonym Names
USH3A; Clarin-1; Usher syndrome type-3 protein homolog
Product Gene Name
CLRN1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q8K445
Specificity
CLRN1 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse CLRN1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CLRN1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CLRN1 sirna
siRNA to inhibit CLRN1 expression using RNA interference
Applications Tested/Suitable for CLRN1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CLRN1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_700433.1
[Other Products]
NCBI GenBank Nucleotide #
NM_153384.3
[Other Products]
UniProt Primary Accession #
Q8K445
[Other Products]
UniProt Secondary Accession #
Q8K446[Other Products]
UniProt Related Accession #
Q8K445[Other Products]
Molecular Weight
27,888 Da
NCBI Official Full Name
clarin-1 isoform 1
NCBI Official Synonym Full Names
clarin 1
NCBI Official Symbol
Clrn1??[Similar Products]
NCBI Official Synonym Symbols
USH3; Ush3a; A130002D11Rik
??[Similar Products]
NCBI Protein Information
clarin-1
UniProt Protein Name
Clarin-1
UniProt Synonym Protein Names
Usher syndrome type-3 protein homolog
UniProt Gene Name
Clrn1??[Similar Products]
UniProt Synonym Gene Names
Ush3a??[Similar Products]
UniProt Entry Name
CLRN1_MOUSE
UniProt Comments for CLRN1
USH3A: May have a role in the excitatory ribbon synapse junctions between hair cells and cochlear ganglion cells and presumably also in analogous synapses within the retina. Defects in CLRN1 are the cause of Usher syndrome type 3A (USH3A). USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa and sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH3 is characterized by postlingual progressive deafness and onset of retinitis pigmentosa in the second decade of life. Defects in CLRN1 are the cause of retinitis pigmentosa type 61 (RP61). RP61 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. Belongs to the clarin family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, multi-pass; Membrane protein, integral
Cellular Component: microvillus; membrane; lamellipodium; plasma membrane; integral to membrane
Biological Process: sensory perception of sound; visual perception; sensory perception of light stimulus; photoreceptor cell maintenance; response to stimulus; cell motility involved in cell locomotion; actin filament organization; auditory receptor cell development; auditory receptor cell stereocilium organization and biogenesis; neuromuscular process controlling balance; equilibrioception
Research Articles on CLRN1
1. A novel synaptic Usher complex comprised of clarin-1 and specific isoforms of CDH23, PCDH15 and VLGR1, was identified.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
